Clinical features | CYP2C9 | CYP1A2 | CYP1B1 | CYP3A4 | CYP2C19 |
---|---|---|---|---|---|
rs1799853 | rs762551 | rs10175368 | rs35599367 | rs4244285 | |
Body mass index b n = 221 | 0.078 | 0.178 | 0.552 | 0.286 | 0.834 |
Age at first pregnancy b n = 195 | 0.144 | 0.292 | 0.179 | 0.032 | 0.785 |
Age at BC diagnosis b n = 221 | 0.511 | 0.675 | 0.295 | 0.391 | 0.132 |
Allergy a n = 221 | 0.721 | 0.927 | 0.859 | 0.146 | 0.920 |
Age at menarche b n = 221 | 0.834 | 0.738 | 0.905 | 0.869 | 0.931 |
Breastfeeding status a n = 221 | 0.250 | 0.450 | 0.196 | 0.009 | 0.161 |
Age at menopause b n = 108 | 0 .356 | 0 .034 | 0 .554 | 0 .161 | 0 .266 |
Family history a n = 221 | 0.562 | 0.167 | 0.521 | 0.494 | 0.294 |
Co-morbidity a n = 221 | 0.659 | 0.456 | 0.774 | 0.822 | 0.349 |
Smoking a n = 216 | 0.305 | 0.705 | 0.899 | 0.341 | 0.528 |
Pathological features | |||||
Progesterone receptor status a n = 198 | 0.213 | 0.118 | 0.378 | 0.554 | 0.213 |
Estrogen receptor status a n = 191 | 0.409 | 0.208 | 0.286 | 0.511 | 0.409 |
Human epidermal growth factor receptor 2 marker (HER2) a n = 139 | 0.495 | 0.028 | 0.109 | 0.566 | 0.495 |
Heteromolecular BC markersa n = 138 | 0.691 | 0.043 | 0.024 | 0.914 | 0.081 |
Tumor differentiation a n = 197 | 0.285 | 0.577 | 0.498 | 0.734 | 0.285 |
Axillary lymph nodes a n = 221 | 0.956 | 0.587 | 0.179 | 0.346 | 0.956 |
Tumor stage a n = 208 | 0.743 | 0.153 | 0.469 | 0.048 | 0.743 |
Histology classification a n = 209 | 0.708 | 0.011 | 0.238 | 0.118 | 0.708 |
Tumor size b n = 208 | 0.407 | 0.433 | 0.991 | 0.318 | 0.407 |
Lymph node involvement a n = 221 | 0.194 | 0.001 | 0.406 | 0.516 | 0.194 |